Last reviewed · How we verify
Povidone-Iodine 0.3%
Povidone-iodine is a broad-spectrum antimicrobial agent that releases iodine to disrupt microbial cell membranes and proteins, killing bacteria, viruses, fungi, and protozoa.
Povidone-iodine is a broad-spectrum antimicrobial agent that releases iodine to disrupt microbial cell membranes and proteins, killing bacteria, viruses, fungi, and protozoa. Used for Skin antisepsis and wound disinfection, Oral and pharyngeal antisepsis, Vaginal antisepsis.
At a glance
| Generic name | Povidone-Iodine 0.3% |
|---|---|
| Sponsor | Norwegian University of Science and Technology |
| Drug class | Topical antiseptic/disinfectant |
| Modality | Small molecule |
| Therapeutic area | Infectious Disease / Dermatology |
| Phase | FDA-approved |
Mechanism of action
The iodine component penetrates microbial cell walls and oxidizes essential proteins and nucleic acids, leading to rapid cell death. Povidone serves as a carrier that stabilizes the iodine and allows sustained release. This non-selective mechanism makes it effective against a wide range of pathogens, though it does not target specific molecular receptors.
Approved indications
- Skin antisepsis and wound disinfection
- Oral and pharyngeal antisepsis
- Vaginal antisepsis
- Prevention of infection in minor cuts, scrapes, and burns
Common side effects
- Skin irritation or sensitization
- Allergic contact dermatitis
- Iodine hypersensitivity reactions
- Staining of skin and clothing
Key clinical trials
- Evaluating XPERIENCE™ Advanced Surgical Irrigation (NA)
- Comparison of the Effects of Bilateral Transversus Abdominis Plane Block and Bilateral Quadratus Lumborum Block on Postoperative Analgesia in Patients Undergoing Midline Laparotomy (NA)
- Optimizing Preoperative Disinfection of Eyes (PHASE4)
- FST-201 in the Treatment of Acute Otitis Externa (PHASE3)
- The Effect of Aromatherapy on the Insulin Injection Pain (NA)
- Reducing Bacteria That Cause Tooth Decay (PHASE3)
- Effect of Intravitreal Bone Marrow Stem Cells on Ischemic Retinopathy (NA)
- Bacterial Resistance in Patients Receiving Post-Intravitreal Injection Antibiotics (NA)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Povidone-Iodine 0.3% CI brief — competitive landscape report
- Povidone-Iodine 0.3% updates RSS · CI watch RSS
- Norwegian University of Science and Technology portfolio CI